DDrare: Database of Drug Development for Rare Diseases

40. Takayasu arteritis
[ 16 clinical trials, 23 drugs（DrugBank: 16 drugs), 16 target genes / 94 target pathways ]

Searched query = "Takayasu arteritis", "Aortitis syndrome", "Pulseless disease"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/20/2019, 11/21/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.

Drug = Acetate; Anti-thymocyte globulin; Clofarabine; Cyclophosphamide; Cyclosporine; Filgrastim; Fluorine f 18; Glucocorticoids; Infliximab; Leflunomide; Leflunomide 10mg tab; Methylprednisolone; Naltrexone; Naltrexone hydrochloride; Placebo; Prednisone; Prednisone acetate; Prednisone, cyclophosphamide; Remicade (anti tumor necrosis factor inhibitor); Tocilizumab; Tocilizumab (mra-sc); Yellow fever vaccine; Yellow fever vaccine (17d)

No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03482479	February 4, 2019	22 October 2019	Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis	Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis	Eosinophilic Granulomatosis With Polyangiitis (EGPA);Churg-Strauss Syndrome (CSS);Giant Cell Arteritis;Granulomatosis With Polyangiitis;Microscopic Polyangiitis;Polyarteritis Nodosa;Takayasu Arteritis	Drug: Naltrexone Hydrochloride;Other: Placebo Comparator	University of Pennsylvania		Recruiting	18 Years	N/A	All	60	Phase 2	United States
2	NCT03550781	June 1, 2018	18 June 2018	Anti-inflammatory Treatment for Inactive Takayasu Arteritis	Does Inactive Takayasu Arteritis(NIH Criteria) Need Anti-inflammatory Treatment?	Takayasu Arteritis;Anti-Inflammatory Agents	Drug: Prednisone, cyclophosphamide	Chinese Academy of Medical Sciences, Fuwai Hospital		Not recruiting	10 Years	40 Years	All	40	Phase 2/Phase 3
3	NCT03430388	January 31, 2018	6 May 2019	Yellow Fever Vaccine in Patients With Rheumatic Diseases	Evaluation of Yellow Fever Vaccine in Patients With Rheumatic Diseases Under Low Immunosuppression Level and Residing in a Risk Area	Systemic Lupus;Rheumatoid Arthritis;Spondyloarthritis;Inflammatory Myopathy;Systemic Sclerosis;Mixed Connective Tissue Disease;Takayasu Arteritis;Granulomatosis With Polyangiitis;Sjogren's Syndrome;Juvenile Idiopathic Arthritis;Juvenile Dermatomyositis	Biological: Yellow Fever vaccine (17D)	University of Sao Paulo General Hospital		Not recruiting	2 Years	60 Years	All	600	N/A	Brazil
4	NCT03096275	March 16, 2017	16 December 2017	Comparison of Mycophenolate Mofetil and Cyclophosphamide for Active Takayasu's Arteritis	Comparison of the Efficacy of Mycophenolate Mofetil Combined With Methotrexate and Cyclophosphamide for the Treatment of Takayasu's Arteritis	Takayasu Arteritis	Drug: MMF;Drug: CYC;Drug: Glucocorticoids;Drug: MTX;Drug: AZA	Chinese SLE Treatment And Research Group	Peking Union Medical College Hospital	Recruiting	18 Years	N/A	All	150	Phase 3	China
5	NCT03192878	March 1, 2017	16 December 2017	Infliximab Biosimilar in Takayasu's Arteritis	A Prospective Observational Study of Infliximab Biosimilar in the Treatment of Takayasu's Arteritis Resistant to Corticosteroids and Conventional Immune-suppressive Treatments	Takayasu Arteritis	Drug: Infliximab	Ospedale San Raffaele		Recruiting	18 Years	N/A	All	30	N/A	Italy
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
6	JPRN-UMIN000025940	2017/02/07	2 April 2019	Clinical Research on the Safety of anti-interleukin-6 antibody (Tocilizumab) treatment for the refractory patients with Takayasu Arteritis		Takayasu arteritis	Intravenous administration of tocilizumab (8mg/kg/month) for up to 12 months	Osaka University	National Cerebral and Cardiovascular Center	Not Recruiting	16years-old	60years-old	Male and Female	2	Not selected	Japan
7	NCT02981979	December 2016	4 March 2019	Takayasu Arteritis Clinical Trial in China	Comparison of the Efficacy and Safety of Leflunomide Versus Placebo Combine With the Basic Prednisone Therapy in Patients With Active Phase of Takayasu's Arteritis: a Randomized Controlled Double-blinded Trial	Takayasu Arteritis	Drug: Leflunomide 10mg Tab;Drug: Prednisone Acetate;Drug: Placebos	Jiang lindi		Recruiting	18 Years	65 Years	All	116	N/A	China
8	NCT03893136	November 1, 2016	8 April 2019	The Registry Study of Takayasu Arteritis in East China	The Cohort Study of East Chinese Takayasu's Arteritis (ECTA-cohort Study)	Takayasu Arteritis;Mechanisms, Defense;Pregnancy Related;Treatment Refusal;Outcome	Biological: Tocilizumab;Drug: Leflunomide	Shanghai Zhongshan Hospital		Recruiting	18 Years	65 Years	All	1000	N/A	China
9	NCT02925351	January 25, 2016	11 November 2019	Fluorine F 18 Clofarabine PET/CT in Imaging Patients With Autoimmune or Inflammatory Diseases	The Biodistribution of 18F-Clofarabine in Patients With Autoimmune and Inflammatory Diseases	Autoimmune Disease;Crohn Disease;Inflammatory Disorder;Rheumatoid Arthritis;Systemic Lupus Erythematosus;Takayasu Arteritis	Procedure: Computed Tomography;Radiation: Fluorine F 18 Clofarabine;Procedure: Positron Emission Tomography	Jonsson Comprehensive Cancer Center	National Cancer Institute (NCI)	Not recruiting	18 Years	N/A	All	8	N/A	United States
10	NCT02457585	March 2015	16 December 2017	Clinical Study of Anti-tumor Necrosis Factor Therapy in Patients With Takayasu Arteritis	Anti-tumor Necrosis Factor Therapy Effect on Takayasu Arteritis	Takayasu's Arteritis	Drug: remicade (anti tumor necrosis factor inhibitor)	Seoul National University Hospital		Recruiting	18 Years	N/A	All	11	Phase 2	Korea, Republic of
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
11	JPRN-UMIN000025943	2014/08/07	2 April 2019	Long-term Safety of treatment with tocilizumab in the refractory patients with Takayasu Arteritis		Takayasu arteritis	Intravenous administration of tocilizumab (8mg/kg/month) will be performed until December 31st, 2017.	Osaka Unversity	National Cerebral and Cardiovascular Center	Not Recruiting	16years-old	60years-old	Male and Female	9	Not selected	Japan
12	NCT02101333	June 10, 2014	16 December 2017	Efficacy and Tolerance of Tocilizumab In Takayasu Arteritis	Efficacy and Tolerance of First-line Treatment With Tocilizumab in Active Takayasu Arteritis French Prospective Multicenter Study	TAKAYASU ARTERITIS	Drug: Tocilizumab	Assistance Publique - Hôpitaux de Paris	Chugai Pharmaceutical	Recruiting	18 Years	77 Years	All	15	Phase 3	France
13	JPRN-JapicCTI-142616	01/6/2014	2 April 2019	Phase III Study of MRA-SC in Patients with Takayasu Arteritis	A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III Study of MRA-SC in Patients with Takayasu Arteritis	Takayasu Arteritis	Intervention name : tocilizumab (MRA-SC) Dosage And administration of the intervention : 162mg/W, SC Control intervention name : Placebo Dosage And administration of the control intervention : Placebo/W, SC	Chugai Pharmaceutical Co., Ltd.			12		BOTH	34	Phase 3
14	JPRN-UMIN000008812	2012/10/01	2 April 2019	Efficacy and safety of tocilizumab mono-therapy in patients with large vessel vasculitis (LVV; giant cell arteritis or Takayasu arteritis) and polymyalgia rheumatica (PMR)		Rheumatoid arthritis	tocilizumab monotherapy	Department of Rheumatology & Clinical Immunology Saitama Medical Center, Saitama Medical Universitity		Not Recruiting	16years-old	80years-old	Male and Female	40	Not selected	Japan
15	JPRN-UMIN000007845	2012/05/01	2 April 2019	Efficacy and Safety of treatment with tocilizumab in refractory patients with Takayasu Arteritis		Takayasu arteritis	Intravenous administration of tocilizumab (8mg/kg/month) for 24 months	Department of Cardiovascular Medicine Graduate School of Medicine Osaka University		Not Recruiting	16years-old	60years-old	Male and Female	15	Not selected	Japan
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
16	NCT00006055	March 2000	19 February 2015	Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases		Purpura, Schoenlein-Henoch;Graft Versus Host Disease;Anemia, Hemolytic, Autoimmune;Rheumatoid Arthritis;Churg-Strauss Syndrome;Hypersensitivity Vasculitis;Wegener's Granulomatosis;Systemic Lupus Erythematosus;Giant Cell Arteritis;Pure Red Cell Aplasia;Juvenile Rheumatoid Arthritis;Polyarteritis Nodosa;Autoimmune Thrombocytopenic Purpura;Takayasu Arteritis	Drug: anti-thymocyte globulin;Drug: cyclophosphamide;Drug: cyclosporine;Drug: filgrastim;Drug: methylprednisolone;Drug: prednisone;Procedure: Autologous Peripheral Blood Stem Cell Transplantation	Fairview University Medical Center		Not recruiting	1 Year	55 Years	Both	10	N/A	United States